Finally, in a clinical trial of tocilizumab, the IL6 trans-signaling blocking drug, ALS patients who received the treatment exhibited a significant reduction in plasma levels of C-reactive protein (CRP), indicating functional inhibition of IL6 signaling. This evidence concerns the gene CRP and amyotrophic lateral sclerosis.